Back to top
more

Cybin Inc. (CYBN)

(Delayed Data from AMEX)

$0.35 USD

0.35
2,826,997

-0.01 (-2.54%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $0.34 -0.01 (-1.73%) 5:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CYBN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cybin Inc. [CYBN]

Reports for Purchase

Showing records 1 - 20 ( 46 total )

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

03/21/2024

Industry Report

Pages: 8

Key Takeaway From Biotech Breakthroughs Psychiatry Event

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

03/14/2024

Daily Note

Pages: 3

Reaches Regulatory Alignment For CYB003 in Depression; Phase 3 to Start in Mid-2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

03/13/2024

Daily Note

Pages: 4

CYB003 Clears Phase 2 Hurdle in Depression; Program Expected to Move to Phase 3 in Mid-2024; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 10.00

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

02/15/2024

Company Report

Pages: 7

F3Q24 Results; Depression Program Expected to Move Into Phase 3 in 2Q24 Pending Regulatory Feedback; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

01/04/2024

Daily Note

Pages: 3

Lead Depression Program on Track for Phase 3 Start by 1Q24

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/01/2023

Company Report

Pages: 10

RD Event Reinforces Positive Data in Phase 2 MDD Trial With Psychedelic CYB003; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

11/17/2023

Company Report

Pages: 8

Announces RD Briefing on November 30; Lead Depression Program on Track for Phase 3; Moderating PT to $5; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/02/2023

Company Report

Pages: 8

CYB003 on Track to Clear Phase 2 Hurdle in Depression

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/31/2023

Daily Note

Pages: 4

Lead Psychedelic Program CYB003 Generates Promising Interim Data in Phase 2 Depression Trial

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 5.00

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

10/02/2023

Company Report

Pages: 7

DMT Program Clears Another Hurdle

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/29/2023

Company Report

Pages: 7

Acquires Small Pharma, Strengthening IP Position in Short-Acting Psychedelics; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

08/15/2023

Company Report

Pages: 7

F1Q24 Results; Psychedelic Programs in Depression and Anxiety Topline Data Expected 2H23; Patent Granted; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

07/17/2023

Industry Report

Pages: 11

Takeaways From Recent Conferences: Nearing a Psychedelic Breakout With Plethora of Catalysts; LP352 to Shine in Epilepsy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

06/30/2023

Company Report

Pages: 9

Data Readouts on Psychedelic Compounds CYB003 in Depression and CYB004 in Anxiety on Track for 2H23; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

03/10/2023

Company Report

Pages: 13

Clearing First Hurdle, CYB003 Poised for Positive Top-Line Data in Phase 1/2a Trial in 3Q23; CYB004 Advances; Reit. Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 25.00

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

02/15/2023

Company Report

Pages: 8

F3Q23 Results; Unveiling of Interim Phase 1 Data on Lead Compound CYB003 Expected on February 28; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

01/26/2023

Industry Report

Pages: 10

Bullish Start to the Year for Psychedelic Drug Development Companies Ahead of a Plethora of Potential Positive Events

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

12/16/2022

Company Report

Pages: 10

Compelling Preclinical Data Presented at ACNP Points to Potential Differentiation of CYB003; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

11/17/2022

Company Report

Pages: 8

F2Q23 Results; Lead Psychedelic Program CYB003 on Track in Depression; Improves Intellectual Property Positioning

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 12.50

Research Provided by a Third Party

Company: Cybin Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

09/22/2022

Industry Report

Pages: 32

JAMA Publication Further Supports Psychedelic Approach to Treat Alcoholism, a Potential $20B-Plus Global Market

Provider: H.C. Wainwright & Co., Inc.

Analyst: TRUCCHIO P

Price: 35.00

Research Provided by a Third Party